Real-world evidence platform for clinical research in hepatology and GI diseases
Target RWE acquired by Highlander Health in January 2025, operates a clinical evidence platform built on Python, Spark, and multi-cloud infrastructure (AWS, GCP, Azure). The tech stack—LLM frameworks (Langchain, LangGraph), data validation tooling, and observability systems—maps directly to their core pain points: data reliability, pipeline quality, and study reproducibility. Active hiring is research-heavy (5 roles) with a single engineering position, suggesting they're scaling analytical capacity faster than infrastructure, likely to handle hepatology and GI specialty datasets at scale.
Target RWE builds infrastructure for clinical evidence generation, partnering with health systems and key opinion leaders to conduct real-world studies in hepatology, gastroenterology, and dermatology. The platform integrates retrospective data analysis (via Epic, Cerner, and FHIR/HL7 integration) with prospective study design, allowing researchers to uncover treatment efficacy and safety outcomes grounded in actual patient data rather than trial settings alone. Operations span financial management (Sage Intacct, Bill.com, Concur) and CRM (Salesforce), anchored in Durham, North Carolina. The company is currently focused on three specialty areas but signals expansion of product breadth and service offerings.
Python, Apache Spark, Dask for analytics; Epic Systems and Cerner for EHR integration; FHIR and HL7 for interoperability; PostgreSQL for persistence; AWS, GCP, Azure for compute.
Hepatology real-world evidence studies, prospective clinical studies, scalable ML systems for healthcare analytics, LLM translation to production, and drift detection and observability tooling for data pipelines.
Target RWE's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.